What side effects should I discuss with a panic disorder patient during a NAC OSCE (National Assessment Center Objective Structured Clinical Examination) regarding SSRIs (selective serotonin reuptake inhibitors) and SNRIs (serotonin‑norepinephrine reuptake inhibitors)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 6, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Side Effects to Discuss with Panic Disorder Patients About SSRIs and SNRIs

When counseling a panic disorder patient about SSRIs and SNRIs, you must discuss both common side effects that affect quality of life and rare but serious adverse events that impact morbidity and mortality, with particular emphasis on suicidal thinking in younger patients and discontinuation syndrome.

Common Side Effects (Affecting Quality of Life)

SSRIs - Most Frequent Side Effects 1

  • Gastrointestinal: Nausea (most common), diarrhea, heartburn, dry mouth
  • Neurological: Headache, dizziness, tremor, vivid dreams
  • Sleep-related: Insomnia or somnolence (can go either way)
  • Autonomic: Diaphoresis (sweating), nervousness
  • Other: Changes in appetite, weight changes, fatigue, bruxism (teeth grinding)

SNRIs - Most Frequent Side Effects 1

  • Gastrointestinal: Nausea, vomiting, diarrhea, abdominal discomfort, dry mouth
  • Neurological: Headache, dizziness, tremor
  • Sleep-related: Insomnia or somnolence
  • Cardiovascular: Increased blood pressure and pulse (unique to SNRIs - requires monitoring)
  • Autonomic: Diaphoresis (sweating)
  • Other: Decreased appetite, weight loss

Key Clinical Point: Most common side effects emerge within the first few weeks of treatment 1. SNRIs uniquely cause sustained hypertension and increased pulse, requiring blood pressure monitoring 1.

Serious Adverse Events (Affecting Morbidity/Mortality)

Black Box Warning - Suicidal Thinking and Behavior 1

  • All SSRIs and SNRIs carry FDA black box warning for suicidal thinking/behavior through age 24 years
  • Pooled absolute risk: 1% with antidepressants vs 0.2% with placebo
  • Number needed to harm (NNH): 143
  • Close monitoring required, especially in first months and after dose adjustments

Behavioral Activation/Agitation 1

  • Motor or mental restlessness, insomnia, impulsiveness, talkativeness, disinhibited behavior, aggression
  • More common in younger children than adolescents
  • Occurs early in treatment or with dose increases
  • Usually improves quickly after dose reduction

Serotonin Syndrome 1

  • Life-threatening condition caused by elevated brain serotonin
  • Symptoms within 24-48 hours of combining serotonergic medications:
    • Mental status changes (confusion, agitation, anxiety)
    • Neuromuscular hyperactivity (tremors, clonus, hyperreflexia, muscle rigidity)
    • Autonomic hyperactivity (hypertension, tachycardia, diaphoresis, fever)
  • Advanced symptoms: seizures, arrhythmias, unconsciousness, death
  • Contraindicated with MAOIs

Other Serious Adverse Events 1

  • Hypomania/mania (rare, may appear later in treatment)
  • Sexual dysfunction (erectile dysfunction, delayed ejaculation, anorgasmia in adolescents)
  • Seizures (use cautiously in patients with seizure history)
  • Abnormal bleeding (especially with NSAIDs or aspirin)

SNRI-Specific Serious Adverse Events 1

Venlafaxine:

  • Greater suicide risk than other SNRIs
  • Associated with overdose fatalities
  • Prominent discontinuation symptoms

Duloxetine:

  • Hepatic failure (abdominal pain, hepatomegaly, elevated transaminases, cholestatic jaundice)
  • Severe skin reactions (erythema multiforme, Stevens-Johnson syndrome)
  • Discontinue immediately if jaundice, liver dysfunction, or skin reactions occur

Discontinuation Syndrome 1

Both SSRIs and SNRIs cause discontinuation syndrome with missed doses or abrupt cessation:

  • Dizziness, fatigue, lethargy, general malaise
  • Myalgias, chills, headaches
  • Nausea, vomiting, diarrhea
  • Insomnia, imbalance, vertigo
  • Sensory disturbances, paresthesias
  • Anxiety, irritability, agitation

Paroxetine has highest risk among SSRIs 1 Venlafaxine has prominent discontinuation symptoms among SNRIs 1

Clinical Action: Always taper slowly when discontinuing 1

Tolerability Comparison

Research shows that SSRIs and SNRIs cause more dropouts due to adverse effects than placebo 2, 3. However, among SSRIs, sertraline and escitalopram have the most favorable tolerability profiles for panic disorder 4.

Monitoring Requirements

For All Patients 1

  • Close monitoring for suicidality, especially first months and after dose changes
  • Watch for behavioral activation in first month

SNRI-Specific Monitoring 1

  • Height, weight, pulse, and blood pressure at each visit
  • No specific laboratory tests routinely recommended
  • Consider liver function tests if using duloxetine and patient develops symptoms

Common Pitfalls to Avoid

  1. Starting at full therapeutic dose: Begin with subtherapeutic "test" dose to minimize initial anxiety/agitation 1
  2. Rapid up-titration: Use slow titration (1-2 weeks for short half-life SSRIs, 3-4 weeks for long half-life) 1
  3. Abrupt discontinuation: Always taper slowly to avoid discontinuation syndrome 1
  4. Missing cardiovascular monitoring with SNRIs: Blood pressure and pulse must be monitored 1
  5. Combining with MAOIs: Absolutely contraindicated due to serotonin syndrome risk 1

References

1
Guideline

clinical practice guideline for the assessment and treatment of children and adolescents with anxiety disorders.

Journal of the American Academy of Child and Adolescent Psychiatry, 2020

3
Research

Antidepressants versus placebo for panic disorder in adults.

The Cochrane database of systematic reviews, 2018

Related Questions

For a patient experiencing two panic attacks per month, is it appropriate to initiate a selective serotonin reuptake inhibitor (SSRI)?
What are the recommended first‑line SNRI choices, dosing regimens, and monitoring parameters for a patient with comorbid anxiety and depression?
I am taking fluoxetine (Prozac) 60 mg daily for anxiety but still have persistent generalized unease without palpitations; should I switch to an SNRI, and which SNRI would be appropriate?
What is the recommended next treatment approach for a female patient with severe anxiety and hypervigilance who has not responded to SSRI or SNRI therapy?
What selective serotonin reuptake inhibitor (SSRI) is appropriate for a 14-year-old male of Asian descent with panic disorder?
In a neonate with abnormal mandibular morphology, dental‑arch asymmetry, and a deviated mouth corner when crying, what are the possible causes and the optimal diagnostic and treatment approach?
What is the recommended verapamil dosing regimen for managing tachycardia?
What is the most common accompanying illness in exanthema subitum (roseola infantum)?
What is the recommended approach for assessing, treating, and following up patients with ADHD in primary care, including medication choices (stimulants, atomoxetine, guanfacine, clonidine, bupropion), dosing regimens, monitoring parameters, and follow‑up intervals for children, adolescents, and adults?
What oral medication can be used to treat tachycardia in a patient with stable lung disease?
How should hypotension be managed in a patient with stage 4 chronic kidney disease?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.